| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| A1029-100 | Anti-human DDR1 Antibody mIgG2a | 100µg | $185 | Order |
| A1029-200 | Anti-human DDR1 Antibody mIgG2a | 200µg | $325 | Order |
| A1029-500 | Anti-human DDR1 Antibody mIgG2a | 500µg | $545 | Order |
| Catalog Number | A1029 |
|---|---|
| Product Name | Anti-human DDR1 antibody, mIgG2a |
| Source | Derive from mouse hybridoma, mouse immunized with human DDR1 extra cellular domain |
| Clone | Z8BS4 |
| Species Reactivity | Human |
| Isotype | Mouse IgG2a |
| Purity | >95% |
| Formulation | 1x PBS, pH 6.8; Sterile |
| Stability & Storage | 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw |
| Protein Aggregation | Not obvious on SDS-PAGE |
| Application | Flow cytometry, ELISA, cell-based assay |
| Product Datasheet: | Download PDF |
Detection of human DDR1 on Human DDR1-CHO-K1 cells (Cat.#C3030) by flow cytometry. Anti-human DDR1 antibody Z8BS4 (Cat.#A1029) was incubated with human DDR1-CHO-K1 cells (Cat.#C3030), followed by staining with PE-anti-mouse IgG.
DDR1 (discoidin domain receptor tyrosine kinase 1), also known as CD167, CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, EDDR1, MCK10, NTRK4, and PTK3A, is a receptor tyrosine kinase (RTK) and belongs to a subfamily of tyrosine kinase receptors with a homology region to the Dictyosteliumdiscoideum protein discoidin I in its extracellular domain. DDR1 consists of three regions (an extracellular ligand binding domain, a transmembrane domain, and an intracellular region containing a kinase domain), with its kinase activity induced by receptor-specific ligand binding. Collagen binding to DDR1 stimulates its autophosphorylation, activating kinase activity and signaling to downstream signaling pathways. DDR1 expression is restricted to epithelial cells, particularly in the kidney, lung, gastrointestinal tract, and brain and is significantly over-expressed in several human tumors from breast, ovarian, esophageal, and brain. DDR1 plays a key role in the development and progression of breast and ovarian cancer and is a promising therapeutic target.
Johnson, J. D., Edman, J. C., Rutter, W. J., Proc. Nat. Acad. Sci. 90: 5677-5681, 1993.
Chen, L., et al, Frontiers in Cell and Dev. Bio. 9: 747314, 2021.
Letinger, B., Int Rev Cell Mol Biol., 310: 39-87, 2014.
Vogel, W., et al., Mol. Cell, 1: 13–23, 1997.